143 related articles for article (PubMed ID: 30845397)
1. [The role and mechanism of 2-deoxyglucose in reversing osimertinib-acquired resistance of non-small cell lung cancer cell line].
Hao S; Lu CH; Lin CC; Chen HY; Li L; Wang YB; Feng MX; He Y
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Mar; 42(3):198-205. PubMed ID: 30845397
[No Abstract] [Full Text] [Related]
2. Characterization of osimertinib (AZD9291)-resistant non-small cell lung cancer NCI-H1975/OSIR cell line.
Tang ZH; Jiang XM; Guo X; Fong CM; Chen X; Lu JJ
Oncotarget; 2016 Dec; 7(49):81598-81610. PubMed ID: 27835594
[TBL] [Abstract][Full Text] [Related]
3. ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.
Liu K; Chen X; Wu L; Chen S; Fang N; Cai L; Jia J
BMC Pulm Med; 2021 May; 21(1):163. PubMed ID: 33992097
[TBL] [Abstract][Full Text] [Related]
4. Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR-mutant non-small cell lung cancer.
Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
Thorac Cancer; 2021 Jun; 12(11):1708-1715. PubMed ID: 33943009
[TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibitor palbociclib overcomes acquired resistance to third-generation EGFR inhibitor osimertinib in non-small cell lung cancer (NSCLC).
Qin Q; Li X; Liang X; Zeng L; Wang J; Sun L; Zhong D
Thorac Cancer; 2020 Sep; 11(9):2389-2397. PubMed ID: 32677256
[TBL] [Abstract][Full Text] [Related]
6. Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
Zang H; Qian G; Zong D; Fan S; Owonikoko TK; Ramalingam SS; Sun SY
Cancer; 2020 Jan; 126(9):2024-2033. PubMed ID: 31999837
[TBL] [Abstract][Full Text] [Related]
7. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
Hayakawa D; Takahashi F; Mitsuishi Y; Tajima K; Hidayat M; Winardi W; Ihara H; Kanamori K; Matsumoto N; Asao T; Ko R; Shukuya T; Takamochi K; Hayashi T; Suehara Y; Takeda Nakamura I; Ueno T; Kohsaka S; Mano H; Takahashi K
Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.
Jiang XM; Xu YL; Huang MY; Zhang LL; Su MX; Chen X; Lu JJ
Acta Pharmacol Sin; 2017 Nov; 38(11):1512-1520. PubMed ID: 28880013
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis.
Zhao W; Yu D; Chen Z; Yao W; Yang J; Ramalingam SS; Sun SY
Cancer Lett; 2021 Oct; 519():141-149. PubMed ID: 34245854
[TBL] [Abstract][Full Text] [Related]
10. Targeting DNA-PK overcomes acquired resistance to third-generation EGFR-TKI osimertinib in non-small-cell lung cancer.
Liang XM; Qin Q; Liu BN; Li XQ; Zeng LL; Wang J; Kong LP; Zhong DS; Sun LL
Acta Pharmacol Sin; 2021 Apr; 42(4):648-654. PubMed ID: 33414509
[TBL] [Abstract][Full Text] [Related]
11. [Mechanism of MALAT1 induced osimertinib resistance in HCC827 lung cancer cells].
Kang XH; Gao YY; Wang Y; Cui YH; Zhao KL; Kou WZ; Miao ZH; Cao F; Gong YB
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):257-262. PubMed ID: 31014050
[No Abstract] [Full Text] [Related]
12. [Gefitinib inhibits glycolysis and induces programmed cell death in non-small cell lung cancer cells].
Zhou Q; Li J; Pang J; Fan F; Li S; Liu H
Nan Fang Yi Ke Da Xue Xue Bao; 2020 Jun; 40(6):884-892. PubMed ID: 32895203
[TBL] [Abstract][Full Text] [Related]
13. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
14. Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway.
Wang J; Ling X; Zhou M; Ding G; Peng B; Wan J
Neoplasma; 2021 May; 68(3):535-545. PubMed ID: 33724860
[TBL] [Abstract][Full Text] [Related]
15. Aspirin sensitizes osimertinib-resistant NSCLC cells in vitro and in vivo via Bim-dependent apoptosis induction.
Han R; Hao S; Lu C; Zhang C; Lin C; Li L; Wang Y; Hu C; He Y
Mol Oncol; 2020 Jun; 14(6):1152-1169. PubMed ID: 32239624
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase 3 Inhibition Overcomes
Tanimoto A; Takeuchi S; Arai S; Fukuda K; Yamada T; Roca X; Ong ST; Yano S
Clin Cancer Res; 2017 Jun; 23(12):3139-3149. PubMed ID: 27986747
[No Abstract] [Full Text] [Related]
17. Disclosing Potential Therapeutic Targets Associated With Osimertinib Resistance in the Non-small Cell Lung Cancer Cell Line H1975.
Tong X; Zhang R; Sun R; Yang W; Sun J; Chen J; Li F
Anticancer Res; 2023 Dec; 43(12):5459-5474. PubMed ID: 38030186
[TBL] [Abstract][Full Text] [Related]
18. Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Liang YC; Wu HG; Xue HJ; Liu Q; Shi LL; Liu T; Wu G
J Huazhong Univ Sci Technolog Med Sci; 2013 Dec; 33(6):845-851. PubMed ID: 24337846
[TBL] [Abstract][Full Text] [Related]
19. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Hsu CC; Liao BC; Liao WY; Markovets A; Stetson D; Thress K; Yang JC
J Thorac Oncol; 2020 Jan; 15(1):50-61. PubMed ID: 31557536
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms analysis for Formononetin counteracted-Osimertinib resistance in non-small cell lung cancer cells: From the insight into the gene transcriptional level.
Yin R; Gao J; Liu Y
Chem Biol Drug Des; 2024 Jan; 103(1):e14435. PubMed ID: 38230781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
